NWP09 in Children With Attention Deficit Hyperactivity Disorder (ADHD)

• Status: Completed
• Trial end date: 2012-10-01
• Target enrollment: 0
• Participant gender: All

Summary

The safety and efficacy of a chewable formulation of extended-release methylphenidate will be studied in children with ADHD

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer
• Treatments: Methylphenidate

Criteria

Inclusion Criteria:

• Children aged 6 to 12 years with ADHD who require pharmacologic treatment for this condition

Exclusion Criteria:

• Other serious illnesses or conditions that would put the patient at particular risk for safety events or would interfere with treatment/assessment of ADHD